Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia

INTRODUCTION: About half of patients with Acute Myeloid Leukemia (AML) are not eligible for Standard Induction Chemotherapy (SIC). Hypomethylating Agents (HMAs) intravenously (IV) or subcutaneously (SC) in a clinical setting are typically offered as an alternative. However, injectable HMAs may be bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Delmas, Audrey, Batchelder, Laurie, Arora, Ira, Bayet, Solene, Bruhn, David, Eberhardt, Alice, Philpott, Stephanie, Rodriguez-Leboeuf, Ana Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202170/
https://www.ncbi.nlm.nih.gov/pubmed/37223688
http://dx.doi.org/10.3389/fonc.2023.1160966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202170/
https://www.ncbi.nlm.nih.gov/pubmed/37223688
http://dx.doi.org/10.3389/fonc.2023.1160966

Ejemplares similares